Skip to main content
. 2019 Feb 14;14(2):e0210891. doi: 10.1371/journal.pone.0210891

Table 2. Summary of pathological complete response rates in different subsets.

Site All (n = 40) HER2+ (n = 15) TNBC (n = 15) HR+ HER2- RS ≥ 25* (n = 10)
Breast only 55(22) 80 (12) 46 (7) 30(3)
Breast and LN 45(18) 80 (12) 40 (5) 10(1)

*HR+ HER2- RS ≥ 25: HR-positive, HER2-non-amplified with recurrence score ≥ 25 HER2+: human epidermal growth factor receptor type 2 amplified; TNBC: triple-negative breast cancer; HR: hormone receptor